5 results about "Lipid disorder" patented technology

The invention discloses an application of polypeptide in prevention and treatment of plateau hepatic lipid accumulation. The amino acid sequence of the polypeptide is shown as SEQ ID NO.1. The polypeptide effectively blocks abnormal lipid deposition in parenchymal liver cells and macrophages in the plateau low-oxygen environment by competitively inhibiting the function of endogenous CIRP. Animal and cell experiments show that the polypeptide can significantly improve liver fatty degeneration caused by plateau exposure, thereby providing a brand new targeted therapy strategy and drug candidate for prevention and treatment of plateau-related non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH) and hepatocellular carcinoma (HCC).

Disclosed herein, are peptides or fragments thereof capable of binding to oxidized lipids, lipid hydroperoxides or lipopolysaccharides, and a pharmaceutical composition containing the peptides or fragments and methods of using to enhance plasma anti-oxidant PON-1 activity, reduce the risk or ameliorating symptoms of a lipid-mediated inflammatory disease or treat a lipid disorder.

The present disclosure provides a combination therapy for treating a liver disease or disorder and / or a lipid disease or disorder in a subject in need thereof. Specifically, the combination therapy comprises administration of rosuvastatin and resmetirom to a subject in need thereof.

This invention discloses a 4D-printed, swallow-friendly, food-grade medicinal gel that simultaneously regulates comorbid glucose and lipid disorders, and its preparation method, belonging to the technical field of food-grade medicinal products. Starting from the complex pathological mechanism of "comorbid glucose and lipid disorders," this invention, based on the theory of "food and medicine homology" and modern systems biology, selects six food-grade medicinal raw materials (Astragalus membranaceus, Pueraria lobata, Morus alba leaf, corn silk, Dioscorea opposita, and Perilla frutescens) and combines them in a specific ratio to exert a synergistic effect of lowering blood sugar and lipids through multiple targets and pathways. Furthermore, it clarifies that its core active ingredients are quercetin, luteolin, and kaempferol, constructing a 4D-printed protective system from raw material combination to active ingredients.